Tubulin polymerization promoting protein 1 (TPPP1)
A DNA-damage induced microtubule regulatory gene

Alice Schofield and Ora Bernard
Cytoskeleton and Cancer Unit; St Vincent’s Institute of Medical Research; Department of Medicine (St. Vincent’s Hospital); University of Melbourne; Melbourne VIC Australia

The eukaryotic cell cycle relies heavily on the mechanical forces vested by the dynamic rearrangement of the microtubule (MT) network. Tubulin Polymerization promoting Protein 1 (TPPP1) alters MT dynamics by driving MT polymerization as well as stabilization, via increasing MT acetylation. It increases MT rigidity, which results in reduced cell proliferation through downregulation of G₁/S-phase and mitosis to G₁-phase cell cycle transitioning. In this communication, we provide further evidence that TPPP1 may be an important regulator of genomic homeostasis. Our preliminary data show that long-term TPPP1 overexpression reduces cell viability via induction of apoptotic cell death pathways. Moreover, induction of DNA-damage results in increased TPPP1 expression, which is inhibited in the absence of expression of the tumor suppressor p53.

Keywords: TPPP1, HDAC6, ROCK, Cdk, Cell cycle, p53, signal transduction

*Correspondence to: Ora Bernard; Email: obernard@svi.edu.au

Submitted: 07/02/2013; Revised: 08/28/2013; Accepted: 08/29/2013

Citation: Schofield A, Bernard O. Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation. J Biol Chem 2013; 288:7907-17; PMID:23355470; http://dx.doi.org/10.1074/jbc.M112.441048

Tubulin Polymerization Promoting Protein 1 (TPPP1)

Tubulin Polymerization Promoting Protein 1 (TPPP1), also known as p25 (protein of MW 25 kDa), is a member of the TPPP family that in vertebrates also includes TPPP2 (p20) and TPPP3 (p18).5,6 It is a ubiquitously expressed unique MAP that functions to increase MT polymerization and MT acetylation, a stabilizing modification.3,5,7,8 At present, the precise mechanism by which TPPP1 increases MT polymerization is unclear. It binds soluble ‘tubulin’ purified from bovine brain,3 however it is not known whether TPPP1 binds to α-tubulin or β-tubulin subunits or to the α-/β-tubulin heterodimer. TPPP1 is a Mg²⁺ dependent GTP-binding protein;8,9 therefore, it may act as a nucleotide exchange co-factor to enhance the polymerizing GTP-tubulin pool and increase the rate of MT polymerization or alternatively, it may act as a scaffold protein to bind and deliver tubulin heterodimers to nascent protofilaments. In contrast, TPPP1 modulates MT acetylation by binding...
to the \(\alpha\)-tubulin deacetylase Histone deacetylase 6 (HDAC6) and inhibiting its activity, resulting in a reciprocal increase in MT acetylation.\(^3\) Our recent work demonstrated that TPPP1 activity is inhibited by its phosphorylation by Rho-associated Coiled-coil kinase (ROCK) and cyclin dependent kinase 1 (Cdk1). Specifically, we show that ROCK-TPPP1 prevents TPPP1 binding and inhibition of HDAC6, whereas Cdk1-TPPP1 signaling inhibits its MT polymerizing activity.\(^1\)

Expression of TPPP1 in cells enhances MT network rigidity through inhibition of HDAC6 activity and the consequential increase in MT acetylation. Early studies suggested that TPPP1 expression prevents the assembly of the mitotic spindle\(^5\) and reduces cell division,\(^8\) whereas ectopic expression of microRNA-206 (miRNA-206), a miRNA shown to reduce TPPP1 levels, increased the number of dividing cells.\(^11\) Our recent study confirmed that TPPP1 overexpression and knockdown increased and decreased cell proliferation, respectively.\(^1\) Interestingly, our analysis revealed that TPPP1 achieves this via reduction of both the G\(_1\)/S-phase and the mitosis to G\(_1\)-phase transitions. More specifically, we show that TPPP1-mediated HDAC6 inhibition delays the G\(_1\)/S-phase transition, whereas its regulation of the G\(_2\)/M-phase transition is dependent on this function and its promotion of MT polymerization. These results provide a compelling argument that TPPP1 is a
significant broad-spectrum enforcer of the cell cycle checkpoints.

If this were the case, then pharmacologically induced DNA-damage might elicit an increase in TPPP1 expression or activity to enforce cell cycle checkpoints enabling the repair of DNA or to induce apoptotic cell death programs. Interestingly, our preliminary data demonstrate that treatment of cells with the intercalator Doxorubicin, the topoisomerase II targeting Etoposide or the alkylating agent Methyl methanesulfonate (MMS) increase TPPP1 expression (Fig. 1A). These data suggest that induction of TPPP1 expression is a general mechanism in response to DNA damage as a means of activating the cell cycle checkpoints. Moreover, long-term expression of TPPP1 reduces cell viability (Fig. 1B-D) via induction of apoptotic cell death (Fig. 1E), thereby adding more credence to the idea that TPPP1 is an important monitor of genomic integrity.

Finally, p53 is an important tumor suppressor gene that acts as a transcriptional regulator of several genes essential for the precise regulation of cell division. Interestingly, during our investigation, we observed that the TPPP1 gene contains a putative p53 response element \[5'-RRRC{-WGWYY}{\text{N0–13}}-RRRCWGWYYY-3'] \[^{12}\] located in intron 1 (Fig. 1F). Given the presence of a p53 binding motif and that TPPP1 expression is increased in response to DNA damage, also an inducer of p53 expression, TPPP1 may be a p53 transcriptionally upregulated gene. Our preliminary analysis of wild-type HCT116 colorectal cells (p53+/+) or HCT116 cells lacking p53 (p53−/−) revealed that in the absence of p53, the increase in TPPP1 expression after DNA-damage was inhibited (Fig. 1G).

**Materials and Methods**

**Plasmids, tissue culture and pharmacological treatments**

All plasmid constructs were generated as previously described. \(^{1}\) U2OS osteosarcoma and HCT116 colorectal carcinoma cells were cultured and maintained in DMEM supplemented with 10% FBS. U2OS cells stably expressing TPPP1 were generated as previously described. \(^{2}\) Drugs used in this study were dissolved in solvents recommended by the manufacturer. Methyl methanesulfonate (MMS; Sigma) treatment was performed with 0.05% MMS 2 h prior to washout and recovery for two hours. Doxorubicin (10 μM; Sigma) and etoposide (10 μM; Sigma) incubations were performed for 16 h.

**Immunoblotting**

Immunoblotting was performed as previously described. \(^{2}\) The following antibodies (Abs) were obtained from Cell Signaling: anti-cleaved PARP and GAPDH-HRP. The anti-TPPP1 Ab was previously described. \(^{3}\) Anti-p53 and anti-H2AX Abs were generous gifts of A/Prof Ygal Haupt (Peter MacCallum Cancer Centre, Melbourne) and Dr Boris Sarcevic (St. Vincent’s Institute, Melbourne), respectively.

**Cell viability assays**

Sub-G₀ cell populations were determined by flow cytometry of Propidium Iodide labeled cells performed as previously described \(^{1}\) and analyzed using the FlowJo (v8.8.6) software. Cell metabolism, as a measure of cell viability, was performed using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit (Promega) by analysis of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] metabolism at 24 h post-plating. Cell viability counts were conducted by seeding cells at a density of 2x10⁵ cells/well in 6-well plates 24 h prior to trypsinization and resuspension in PBS. Equal volumes of cell suspension and 0.4% (w/v) trypsin blue solution were mixed and incubated at room temperature for 5 min. Total cell and dead cell, trypsin blue positive, counts were performed with a hemocytometer using a light microscope.

**Bioinformatics and data analysis**

TPPP1 genomic sequences were obtained from NCBI (AC_000137) and analyzed for the presence of a p53-response element \[5'\text{-RRRCWGWYYY-}{\text{N0–13}}\text{-RRRCWGWYYY-3}'] \(^{4}\) using the ApE software (M. Wayne Davis, University of Utah, http://biologylabs.utah.edu/jorgensen/wayne/apE/). Data are expressed as mean ± SEM of three independent experiments and analyzed by two-tailed unpaired t-tests.

**Conclusion**

In conclusion, we hypothesize that TPPP1 is an important enforcer of the cell cycle checkpoints and that correct regulation of its activity may be important for maintaining tissue homeostasis. Moreover, given its potential role as a tumor suppressor gene, we propose that aberrant inactivation of TPPP1 may initiate the hyper-proliferative stage of cancer development. Specifically, we propose a model whereby TPPP1 transcription is promoted by p53-mediated binding to a response element located in Intron 1 of the TPPP1 gene. As a result of p53-mediated cis-activation of the TPPP1 gene, TPPP1 expression is increased to enforce cell cycle checkpoints. In the case that DNA fidelity is compromised, prolonged p53 and consequential TPPP1 expression contributes to the initiation of apoptotic cell death programs (Fig. 1H).

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors wish to thank A/Prof Ygal Haupt (Tumour Suppressor Laboratory, Peter MacCallum Cancer Institute), A/Prof Jörg Heierhorst (Molecular Genetics Unit, St. Vincent’s Institute) and Dr Boris Sarcevic (Cell cycle and Cancer Unit, St. Vincent’s Institute) for contributing reagents. This research was supported by grants and a fellowship (to O.B.) from the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC), the Cancer Council of Victoria and in part by the Victorian Government’s Operational Infrastructure Support Program. A.V.S was the recipient of an Australian Postgraduate Award and a St Vincent’s Institute Foundation Top-up Scholarship.
References

1. Schofield AV, Gamell C, Suryadinata R, Sarcevic B, Bernard O. Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdki) inhibits microtubule dynamics to increase cell proliferation. J Biol Chem 2013; 288:7907-17; PMID:23595470; http://dx.doi.org/10.1074/jbc.M112.441048

2. Schofield AV, Steel R, Bernard O. Rho-associated coiled-coil kinase (ROCK) protein controls microtubule dynamics in a novel signaling pathway that regulates cell migration. J Biol Chem 2012; 287:43620-9; PMID:23093407 ; http://dx.doi.org/10.1074/jbc.M112.394965

3. Acevedo K, Li R, Soo P, Suryadinata R, Sarcevic B, Valova VA, Graham ME, Robinson PJ, Bernard O. The phosphorylation of p25/TPPP by LIM kinase 1 inhibits its ability to assemble microtubules. Exp Cell Res 2007; 313:4091-106; PMID:18028908 ; http://dx.doi.org/10.1016/j.yexcr.2007.08.012

4. Cook JL, Ré RN, Giardina JF, Fontenot FE, Cheng DY, Alam J. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies. Oncogene 1995; 11:723-33; PMID:7651736

5. Tirián L, Hlavanda E, Oláh J, Horváth I, Orosz F, Szabó B, Kovács J, Szabadi J, Ovádi J. TPPP/p25 promotes tubulin assemblies and blocks mitotic spindle formation. Proc Natl Acad Sci U S A 2003; 100:13976-81; PMID:14623963; http://dx.doi.org/10.1073/pnas.243635100

6. Vinces O, Tokési N, Oláh J, Hlavanda E, Zotter A, Horváth I, Lehoczky A, Tirián L, MedzihradszkyKF, Kovács J, et al. Tubulin polymerization promoting proteins (TPPPs): members of a new family with distinct structures and functions. Biochemistry 2006; 45:13818-26; PMID:17105200; http://dx.doi.org/10.1021/bi061305e

7. Hlavanda E, Kovács J, Oláh J, Orosz F, MedzihradszkyKF, Ovádi J. Brain-specific p25 protein binds to tubulin and microtubules and induces aberrant microtubule assemblies at substoichiometric concentrations. Biochemistry 2002; 41:8657-64; PMID:12093283; http://dx.doi.org/10.1021/bi020140g

8. Lehoczky A, Tirián L, Tokési N, Lénárt P, Szabó B, Kovács J, Ovádi J. Dynamic targeting of microtubules by TPPP/p25 affects cell survival. J Cell Sci 2004; 117:6249-59; PMID:15564385; http://dx.doi.org/10.1242/jcs.01550

9. Zotter A, Bodor A, Oláh J, Hlavanda E, Orosz F, Percez A, Ovádi J. Disordered TPPP/p25 binds GTP and displays Mg2+ -dependent GTPase activity. FEBS Lett 2011; 585:803-8; PMID:21316364; http://dx.doi.org/10.1016/j.febslet.2011.02.006

10. Tokési N, Lehoczky A, Horváth I, Szabó B, Oláh J, Lau P, Ovádi J. TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem 2010; 285:17896-906; PMID:20308065; http://dx.doi.org/10.1074/jbc.M109.096578

11. Lehoczky A, Lau P, Tokési N, Muja N, Hudson LD, Ovádi J. Tubulin polymerization-promoting protein (TPPP/p25) is critical for oligodendrocyte differentiation. Glia 2010; 58:157-68; PMID:19606501; http://dx.doi.org/10.1002/glia.20909

12. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9; PMID:1301998; http://dx.doi.org/10.1038/ng0492-45